Prospective Phase 2 Trial of PSMA-Targeted Molecular Radiotherapy with 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (RESIST-PC): Efficacy Results of the UCLA Cohort [73]. Here, FOLH1 is linked to prostate carcinoma.